The Role of Single Tablet Regimens (STR) & Perspectives on the Future Shape of HIV Treatment & Care
with Dr. Pedro Cahn, Dr. Calvin Cohen and Dr. Jean-Pierre Routy
In this panel moderated by Prof. Pedro Cahn, Drs. Jean-Pierre Routy and Calvin Cohen discuss the release of the first Phase III data from the new once-a-day Quad therapy pill containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate.
The Quad pill was found to be non-inferior to both Atripla®, another single pill regimen, and a combined regimen of atazanavir/ritonavir plus emtricitabine/tenofovir.
This activity is supported by
an educational grant from:
KEY LEARNING POINTS
- Phase III study results comparing a single-pill quad therapy regimen to both Atripla® and a combined regimen of atazanavir/ritonavir plus emtricitabine/tenofovir
- Discussion of the pros and cons of the new booster cobicistat
- Information on screening ART patients for renal side effects
- Treatment issues with the novel non-nucleoside inhibitor rilpivirine
- Overview of new fixed dose tablets coming on the market
Pedro Cahn, MD
Infectious Disease Unit
Juan A Fernandez Hospital
University of Buenos Aires Medical School
Calvin Cohen, MD, MSc
Community Research Initiative
Boston, Massachusetts, USA
Jean-Pierre Routy, MD
Division of Hematology and Immunodeficiency
Royal Victoria Hospital
Professor of Medicine
Montréal, Québec, Canada
You must be logged in to view the complete program
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Pedro Cahn, MD has a financial interest/relationship or affiliation: Merck, GSK/ViiV Healthcare, BMS, Abbott.
Calvin Cohen, MD has a financial interest/relationship or affiliation: Gilead Sciences, Merck, BMS, Janssen Pharmaceuticals, Tobira Therapeutics, ViiV Healthcare.
Jean-Pierre Routy, MD has a financial interest/relationship or affiliation: Gilead Sciences, Merck, ViiV Healthcare, Abbott.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.